EP3525809A4 - Verfahren und zusammensetzungen zur tusc2-immuntherapie - Google Patents

Verfahren und zusammensetzungen zur tusc2-immuntherapie Download PDF

Info

Publication number: EP3525809A4
Authority: EP; European Patent Office
Prior art keywords: tusc2; immunotherapy; compositions; methods; tusc2 immunotherapy
Prior art date: 2016-10-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP17861125.7A

Other languages

English (en)

French (fr)

Other versions

EP3525809B1 (de

EP3525809A1 (de

Inventor

Jack A. Roth

Lin Ji

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Texas System

University of Texas at Austin

Original Assignee

University of Texas System

University of Texas at Austin

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-12

Filing date

2017-10-12

Publication date

2020-06-03

2017-10-12 Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System

2019-08-21 Publication of EP3525809A1 publication Critical patent/EP3525809A1/de

2020-06-03 Publication of EP3525809A4 publication Critical patent/EP3525809A4/de

2026-03-11 Application granted granted Critical

2026-03-11 Publication of EP3525809B1 publication Critical patent/EP3525809B1/de

Status Active legal-status Critical Current

2037-10-12 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Marine Sciences & Fisheries (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

EP17861125.7A 2016-10-12 2017-10-12 Verfahren und zusammensetzungen zur tusc2-immuntherapie Active EP3525809B1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662407329P	2016-10-12	2016-10-12
PCT/US2017/056338 WO2018071668A1 (en)	2016-10-12	2017-10-12	Methods and compositions for tusc2 immunotherapy

Publications (3)

Publication Number	Publication Date
EP3525809A1 EP3525809A1 (de)	2019-08-21
EP3525809A4 true EP3525809A4 (de)	2020-06-03
EP3525809B1 EP3525809B1 (de)	2026-03-11

Family

ID=61906060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17861125.7A Active EP3525809B1 (de)	2016-10-12	2017-10-12	Verfahren und zusammensetzungen zur tusc2-immuntherapie

Country Status (15)

Country	Link
US (3)	US11278592B2 (de)
EP (1)	EP3525809B1 (de)
JP (3)	JP7041136B2 (de)
KR (1)	KR102661905B1 (de)
CN (2)	CN110072540B (de)
AU (2)	AU2017342364B2 (de)
BR (1)	BR112019007365A2 (de)
CA (1)	CA3040458A1 (de)
CL (1)	CL2019001002A1 (de)
IL (2)	IL322445A (de)
MA (1)	MA46542A (de)
MX (1)	MX386249B (de)
RU (1)	RU2755903C2 (de)
SG (1)	SG11201903283UA (de)
WO (1)	WO2018071668A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS61273B1 (sr)	2014-04-30	2021-01-29	Fujifilm Corp	Lipozomska kompozicija i postupak za njeno dobijanje
CN110072540B (zh) *	2016-10-12	2023-06-02	得克萨斯州大学系统董事会	用于tusc2免疫治疗的方法和组合物
ES2984147T3 (es) *	2018-06-20	2024-10-29	Fujifilm Corp	Medicamento combinado que comprende una composición liposómica de gemcitabina encapsulada y bloqueo de punto de control inmunitario
CN116121194B (zh) *	2023-02-27	2023-10-24	山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院)	一种肺癌免疫治疗耐药细胞系及其制备方法和应用
CN116482368B (zh) *	2023-05-09	2025-09-26	扬州大学	一种靶向检测肿瘤来源细胞外囊泡中microRNA的生物传感器的制备方法
WO2025208148A1 (en) *	2024-03-29	2025-10-02	Genprex, Inc.	Maintenance therapy for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150086541A1 (en) *	2013-09-21	2015-03-26	Carlos Estuardo Aguilar-Cordova	Methods of Cytotoxic Gene Therapy To Treat Tumors
US20150297631A1 (en) *	2011-03-02	2015-10-22	Board Of Regents, The University Of Texas System	Tusc2 therapies

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4162282A (en)	1976-04-22	1979-07-24	Coulter Electronics, Inc.	Method for producing uniform particles
US4310505A (en)	1979-11-08	1982-01-12	California Institute Of Technology	Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4533254A (en)	1981-04-17	1985-08-06	Biotechnology Development Corporation	Apparatus for forming emulsions
US5030453A (en)	1983-03-24	1991-07-09	The Liposome Company, Inc.	Stable plurilamellar vesicles
US4728575A (en)	1984-04-27	1988-03-01	Vestar, Inc.	Contrast agents for NMR imaging
US4921706A (en)	1984-11-20	1990-05-01	Massachusetts Institute Of Technology	Unilamellar lipid vesicles and method for their formation
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
IL79559A0 (en)	1986-07-29	1986-10-31	Univ Ramot	Contrast agents for nmr medical imaging
US4728578A (en)	1986-08-13	1988-03-01	The Lubrizol Corporation	Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5397987A (en)	1993-03-03	1995-03-14	Rheometrics, Inc.	Method and apparatus for analyzing samples using nuclear magnetic resonance
AU7326594A (en)	1993-07-09	1995-02-06	Synergen, Inc.	Recombinant ctla4 polypeptides and methods for making the same
US5855911A (en)	1995-08-29	1999-01-05	Board Of Regents, The University Of Texas System	Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
US5844905A (en)	1996-07-09	1998-12-01	International Business Machines Corporation	Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
US6770291B2 (en)	1996-08-30	2004-08-03	The United States Of America As Represented By The Department Of Health And Human Services	Liposome complexes for increased systemic delivery
US6413544B1 (en)	1996-08-19	2002-07-02	The United States Of America As Represented By The Department Of Health And Human Services	Liposome complexes for increased systemic delivery
AU734337B2 (en)	1996-11-21	2001-06-14	Promega Corporation	Alkyl peptide amides and applications
US5891467A (en)	1997-01-31	1999-04-06	Depotech Corporation	Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
JP2001523958A (ja)	1997-03-21	2001-11-27	ブライハムアンドウィミンズホスピタル，インコーポレイテッド	免疫療法のｃｔｌａ−４結合ペプチド
US5994136A (en)	1997-12-12	1999-11-30	Cell Genesys, Inc.	Method and means for producing high titer, safe, recombinant lentivirus vectors
DK1141028T3 (da)	1998-12-23	2010-05-25	Pfizer	Humane monoklonale antistoffer til CTLA-4
US7605238B2 (en)	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
IL148079A0 (en)	1999-08-24	2002-09-12	Medarex Inc	Human ctla-4 antibodies and compositions containing the same
US6680068B2 (en)	2000-07-06	2004-01-20	The General Hospital Corporation	Drug delivery formulations and targeting
AU7333701A (en)	2000-07-10	2002-01-21	Univ Texas	Chromosome 3p21.3 genes are tumor suppressors
WO2002100435A1 (en)	2001-06-11	2002-12-19	Centre Hospitalier Universitaire De Montreal	Compositions and methods for enhancing nucleic acid transfer into cells
CA2456977C (en)	2001-08-16	2011-06-07	The Trustees Of The University Of Pennsylvania	Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
US7901708B2 (en)	2002-06-28	2011-03-08	Protiva Biotherapeutics, Inc.	Liposomal apparatus and manufacturing methods
MXPA05003287A (es)	2002-09-28	2005-07-05	Massachusetts Inst Technology	Influenza terapeutica.
US20040208921A1 (en)	2003-01-14	2004-10-21	Ho Rodney J. Y.	Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
ES2393485T3 (es)	2003-07-02	2012-12-21	Innate Pharma	Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
US7803376B2 (en)	2003-07-24	2010-09-28	Innate Pharma S.A.	Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
EP2287195B1 (de)	2004-07-01	2019-05-15	Novo Nordisk A/S	Pan-kir2dl nk-rezeptor antikörper und deren diagnostische und therapeutische verwendung
CN101103043A (zh)	2005-01-06	2008-01-09	诺和诺德公司	Kir结合剂和使用其的方法
EP3072522B1 (de)	2005-01-06	2019-04-24	Novo Nordisk A/S	Behandlungen und verfahren mit anti-kir-kombination
AU2006220500A1 (en)	2005-03-09	2006-09-14	Board Of Regents, The University Of Texas System	Novel hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
KR101364374B1 (ko)	2005-03-14	2014-02-17	더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템	생활성 ｆｕｓ1 펩티드 및 나노입자-폴리펩티드 복합체
CN101389314A (zh) *	2005-03-14	2009-03-18	得克萨斯大学体系董事会	生物活性fus1肽和纳米颗粒-多肽复合物
RU2494107C2 (ru)	2005-05-09	2013-09-27	Оно Фармасьютикал Ко., Лтд.	Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
AU2006301163B2 (en)	2005-10-14	2012-02-23	Innate Pharma	Compositions and methods for treating proliferative disorders
US20110052570A1 (en)	2005-10-26	2011-03-03	Children's Medical Center Corporation	Method to prognose response to anti-egfr therapeutics
WO2007092944A2 (en) *	2006-02-08	2007-08-16	Introgen Therapeutics, Inc.	Compositions and methods involving gene therapy and proteasome modulation
MX2008013618A (es)	2006-05-09	2008-10-30	Colgate Palmolive Co	Regimen para el cuidado oral.
US20100189723A1 (en)	2007-01-11	2010-07-29	Peter Andreas Nicolai Reumert Wagtmann	Anti-kir antibodies, formulations, and uses thereof
EP1987839A1 (de)	2007-04-30	2008-11-05	I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale	Zytotoxischer monoklonaler Anti-LAG-3-Antikörper und seine Verwendung bei der Behandlung und Vorbeugung von Organtransplantatabstoßung und Autoimmunerkrankungen
HRP20131167T1 (hr)	2007-06-18	2014-01-03	Merck Sharp & Dohme B.V.	Antitijela za humani receptor programirane smrti pd-1
EP2044949A1 (de)	2007-10-05	2009-04-08	Immutep	Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
PT2242773T (pt)	2008-02-11	2017-09-15	Cure Tech Ltd	Anticorpos monoclonais para o tratamento de tumores
WO2009114335A2 (en)	2008-03-12	2009-09-17	Merck & Co., Inc.	Pd-1 binding proteins
WO2010014784A2 (en)	2008-08-01	2010-02-04	Bristol-Myers Squibb Company	Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010098788A2 (en)	2008-08-25	2010-09-02	Amplimmune, Inc.	Pd-i antagonists and methods for treating infectious disease
US8709411B2 (en)	2008-12-05	2014-04-29	Novo Nordisk A/S	Combination therapy to enhance NK cell mediated cytotoxicity
CN102762593B (zh)	2009-07-31	2015-05-20	梅达雷克斯有限责任公司	抗btla的完全人抗体
WO2011026122A2 (en)	2009-08-31	2011-03-03	Amplimmune, Inc.	B7-h4 fusion proteins and methods of use thereof
WO2011066342A2 (en)	2009-11-24	2011-06-03	Amplimmune, Inc.	Simultaneous inhibition of pd-l1/pd-l2
PL3053932T3 (pl)	2010-02-19	2021-03-08	Xencor, Inc.	Nowe immunoadhezyny CTLA4-IG
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN106963947A (zh)	2010-11-22	2017-07-21	伊纳特医药股份有限公司	Nk细胞调节治疗和用于治疗血液恶性疾病的方法
SG10201603962TA (en)	2011-05-25	2016-07-28	Innate Pharma Sa	Anti-kir antibodies for the treatment of inflammatory disorders
US8841418B2 (en)	2011-07-01	2014-09-23	Cellerant Therapeutics, Inc.	Antibodies that specifically bind to TIM3
JP6120848B2 (ja)	2011-08-15	2017-04-26	メディミューン，エルエルシー	抗ｂ７−ｈ４抗体およびその使用
WO2013067492A1 (en)	2011-11-03	2013-05-10	The Trustees Of The University Of Pennsylvania	Isolated b7-h4 specific compositions and methods of use thereof
US20130247924A1 (en)	2012-03-23	2013-09-26	Mark Scatterday	Electronic cigarette having a flexible and soft configuration
WO2013148158A1 (en)	2012-03-30	2013-10-03	President And Fellows Of Harvard College	Laser-actuated therapeutic nanoparticles
JP2014022858A (ja)	2012-07-17	2014-02-03	Murata Mfg Co Ltd	電力増幅器
US9308236B2 (en)	2013-03-15	2016-04-12	Bristol-Myers Squibb Company	Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
SG11201509742QA (en) *	2013-06-03	2015-12-30	Novartis Ag	Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
MX377858B (es)	2013-06-25	2025-03-11	Vaccinex Inc	Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
CA2917858A1 (en)	2013-08-02	2015-02-05	Aduro Biotech Holdings, Europe B.V.	Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
EA034666B1 (ru)	2013-09-13	2020-03-04	Бейджин Свитзерланд Гмбх	Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
SG10201900002QA (en)	2014-01-24	2019-02-27	Dana Farber Cancer Institue Inc	Antibody molecules to pd-1 and uses thereof
WO2016049385A1 (en) *	2014-09-24	2016-03-31	Apellis Pharmaceuticals, Inc.	Methods and compositions for cancer treatment and treatment selection
CN110072540B (zh) *	2016-10-12	2023-06-02	得克萨斯州大学系统董事会	用于tusc2免疫治疗的方法和组合物

2017
- 2017-10-12 CN CN201780076886.XA patent/CN110072540B/zh active Active
- 2017-10-12 WO PCT/US2017/056338 patent/WO2018071668A1/en not_active Ceased
- 2017-10-12 BR BR112019007365-5A patent/BR112019007365A2/pt unknown
- 2017-10-12 MX MX2019004359A patent/MX386249B/es unknown
- 2017-10-12 SG SG11201903283UA patent/SG11201903283UA/en unknown
- 2017-10-12 KR KR1020197013556A patent/KR102661905B1/ko active Active
- 2017-10-12 RU RU2019114031A patent/RU2755903C2/ru active
- 2017-10-12 MA MA046542A patent/MA46542A/fr unknown
- 2017-10-12 EP EP17861125.7A patent/EP3525809B1/de active Active
- 2017-10-12 CA CA3040458A patent/CA3040458A1/en active Pending
- 2017-10-12 IL IL322445A patent/IL322445A/en unknown
- 2017-10-12 AU AU2017342364A patent/AU2017342364B2/en active Active
- 2017-10-12 JP JP2019519701A patent/JP7041136B2/ja active Active
- 2017-10-12 US US16/341,134 patent/US11278592B2/en active Active
- 2017-10-12 CN CN202310535801.7A patent/CN116672456A/zh active Pending
2019
- 2019-04-11 IL IL265965A patent/IL265965B1/en unknown
- 2019-04-12 CL CL2019001002A patent/CL2019001002A1/es unknown
2022
- 2022-02-17 US US17/674,800 patent/US12485159B2/en active Active
- 2022-03-10 JP JP2022037295A patent/JP7825465B2/ja active Active
2023
- 2023-03-15 AU AU2023201601A patent/AU2023201601B2/en active Active
2024
- 2024-02-22 JP JP2024025307A patent/JP2024057000A/ja active Pending
2025
- 2025-08-06 US US19/292,000 patent/US20260027180A1/en active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150297631A1 (en) *	2011-03-02	2015-10-22	Board Of Regents, The University Of Texas System	Tusc2 therapies
US20150086541A1 (en) *	2013-09-21	2015-03-26	Carlos Estuardo Aguilar-Cordova	Methods of Cytotoxic Gene Therapy To Treat Tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT01455389: FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer", CLINICAL TRIALS.GOV, 16 February 2016 (2016-02-16), pages 1 - 6, XP055662768, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT01455389?V_11=View#StudyPageTop> [retrieved on 20200128] *
KAWASHIMA HIROYUKI ET AL: "Synergistic inhibition of EGFR tyrosine kinase activity and NSCLC cell growth by combination treatment with FUS1-nanoparticle and gefitinib", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING; 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US; ANAHEIM, CA, USA, vol. 46, 1 April 2005 (2005-04-01), pages 637, XP008151337, ISSN: 0197-016X *
LU CHARLES ET AL: "Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans", PLOS ONE,, vol. 7, no. 4, 1 April 2012 (2012-04-01), pages e34833 - 1, XP008152962, ISSN: 1932-6203, [retrieved on 20120425], DOI: 10.1371/JOURNAL.PONE.0034833 *
See also references of WO2018071668A1 *
W.-G. DENG ET AL: "Synergistic Tumor Suppression by Coexpression of FUS1 and p53 Is Associated with Down-regulation of Murine Double Minute-2 and Activation of the Apoptotic Protease-Activating Factor 1-Dependent Apoptotic Pathway in Human Non-Small Cell Lung Cancer Cells", CANCER RESEARCH, vol. 67, no. 2, 15 January 2007 (2007-01-15), pages 709 - 717, XP055025526, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-3463 *

Also Published As

Publication number	Publication date
JP7041136B2 (ja)	2022-03-23
CL2019001002A1 (es)	2019-11-08
US12485159B2 (en)	2025-12-02
CN110072540B (zh)	2023-06-02
IL265965B1 (en)	2026-01-01
EP3525809B1 (de)	2026-03-11
IL265965A (en)	2019-06-30
CA3040458A1 (en)	2018-04-19
AU2023201601B2 (en)	2026-02-05
BR112019007365A2 (pt)	2019-07-09
RU2019114031A (ru)	2020-11-13
CN110072540A (zh)	2019-07-30
EP3525809A1 (de)	2019-08-21
IL322445A (en)	2025-09-01
AU2017342364B2 (en)	2022-12-15
KR102661905B1 (ko)	2024-04-29
JP2019534268A (ja)	2019-11-28
SG11201903283UA (en)	2019-05-30
KR20190067216A (ko)	2019-06-14
AU2017342364A1 (en)	2019-05-23
US11278592B2 (en)	2022-03-22
US20200038480A1 (en)	2020-02-06
CN116672456A (zh)	2023-09-01
JP7825465B2 (ja)	2026-03-06
JP2022081616A (ja)	2022-05-31
AU2023201601A1 (en)	2023-04-13
MX386249B (es)	2025-03-18
RU2755903C2 (ru)	2021-09-22
US20220168388A1 (en)	2022-06-02
US20260027180A1 (en)	2026-01-29
WO2018071668A1 (en)	2018-04-19
MA46542A (fr)	2021-03-31
JP2024057000A (ja)	2024-04-23
RU2019114031A3 (de)	2020-11-13

Legal Events

Date	Code	Title	Description
2018-04-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-07-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-07-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-08-21	17P	Request for examination filed	Effective date: 20190507
2019-08-21	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-08-21	AX	Request for extension of the european patent	Extension state: BA ME
2020-06-03	A4	Supplementary search report drawn up and despatched	Effective date: 20200504
2020-06-03	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 14/47 20060101ALI20200424BHEP Ipc: A61P 35/00 20060101ALI20200424BHEP Ipc: C07K 16/28 20060101ALI20200424BHEP Ipc: A61K 48/00 20060101ALI20200424BHEP Ipc: A61K 39/395 20060101ALI20200424BHEP Ipc: A61K 38/17 20060101AFI20200424BHEP
2020-07-24	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40012448 Country of ref document: HK
2021-02-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-03-31	17Q	First examination report despatched	Effective date: 20210302
2025-04-03	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2025-04-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2025-05-07	INTG	Intention to grant announced	Effective date: 20250404
2025-08-04	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2025-08-04	GRAL	Information related to payment of fee for publishing/printing deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR3
2025-08-04	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2025-08-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2025-09-03	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2025-09-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2025-09-10	INTC	Intention to grant announced (deleted)
2025-09-10	P01	Opt-out of the competence of the unified patent court (upc) registered	Free format text: CASE NUMBER: UPC_APP_2615_3525809/2025 Effective date: 20250806
2025-10-08	INTG	Intention to grant announced	Effective date: 20250904
2025-12-19	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2025-12-19	GRAL	Information related to payment of fee for publishing/printing deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR3
2025-12-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2026-01-13	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2026-01-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2026-01-21	INTC	Intention to grant announced (deleted)
2026-02-06	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2026-02-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2026-02-11	INTG	Intention to grant announced	Effective date: 20260113
2026-03-11	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2026-03-11	REG	Reference to a national code	Ref country code: CH Ref legal event code: F10 Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260311 Ref country code: GB Ref legal event code: FG4D
2026-04-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602017094293 Country of ref document: DE
2026-04-08	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D

Publication	Publication Date	Title
EP3493827A4 (de)	2020-02-26	Zusammensetzungen und verfahren für die immuntherapie
IL286103B (en)	2022-06-01	Crispr-cas-related methods, compositions and components for cancer immunotherapy
IL286025A (en)	2021-10-31	Nanoparticle preparations and immunotherapy methods
EP3471745A4 (de)	2020-01-22	Verfahren und zusammensetzungen zur reduzierung von oxidativem stress
IL265844A (en)	2019-06-30	Anti-lag-3 antibodies and preparations
IL261163B (en)	2022-10-01	Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
EP3405577A4 (de)	2019-09-11	Zusammensetzungen und verfahren zur hemmung des faktors d
IL262176A (en)	2018-11-29	Anti-tim-3 antibodies and preparations
IL256295A (en)	2018-02-28	Anti-ntb-a antibodies and related compositions and methods
EP3519946A4 (de)	2020-03-11	Hardware-beschleuniger und verfahren für offload-operationen
EP3405190A4 (de)	2019-10-30	Verfahren zur auslösung einer immunreaktion
EP3356390A4 (de)	2019-08-28	Verfahren und zusammensetzungen für antikörperausweichende virusvektoren
EP3328377A4 (de)	2019-03-13	Zusammensetzungen und verfahren für immun-onkologie-therapien
EP3331571A4 (de)	2019-04-10	Zusammensetzungen und verfahren zur behandlung von virusinfektionen
EP3126524A4 (de)	2017-09-20	Verbesserte zusammensetzungen und verfahren für molekularinversionsprobenassays
MA41863A (fr)	2021-06-02	Compositions et procédés permettant de traiter une anémie
EP3503879A4 (de)	2020-04-29	Zusammensetzung und verfahren dafür
EP3448981A4 (de)	2019-11-27	Zusammensetzungen und verfahren zur durchführung von magnetschwebetrennungen
EP3307296A4 (de)	2019-01-16	Verfahren und zusammensetzungen zur behandlung von altersassoziierten leiden
EP3525809A4 (de)	2020-06-03	Verfahren und zusammensetzungen zur tusc2-immuntherapie
EP3298151A4 (de)	2019-04-10	Verfahren und zusammensetzungen zur bestimmung des ph-wertes
EP3429690A4 (de)	2019-10-23	Verfahren zur modulation von keap1
EP3350338A4 (de)	2019-07-17	Verfahren und zusammensetzungen zur detektion von mykotoxinen
EP3600399A4 (de)	2021-03-24	Verfahren und zusammensetzungen zur impfung gegen malaria
EP3319930A4 (de)	2019-04-10	Verfahren und zusammensetzungen zur stabilisierung von proteinen